Advanced non-small cell lung cancer in elderly patients: A review

Table 1 Results from phase III trials of advanced non-small-cell lung cancer in elderly patients: Non-platinum based chemotherapy

Ref.	Regimen	Age (yr)	No. of patients	RR (%)	MST (mo)
Gridelli[11]	Vinorelbine	70	76	20	6.5
	vs
	Best Supportive Care		78	NA	4.8
Frasci et al[23]	Vinorelbine	70	60	15	4.2
	vs
	Vinorelbine + Gemcitabine		60	22	6.7
Gridelli et al[24]	Vinorelbine or	70	233	18	8.3
	Gemcitabine		233	16	6.5
	vs
	Vinorelbine + Gemcitabine		232	21	6.9
Kudoh et al[22]	Vinorelbine	≥ 70	91	9.9	9.9
	vs
	Docetaxel		88	22.7	14.3
Quoix et al[54]	Vinorelbine or Gemcitabine	≥ 70	226		10.3
	vs
	Carboplatin/paclitaxel		225		6.2
Hainsworth et al[25]	Docetaxel	≥ 65	171	17	5.1
	vs
	Docetaxel/gemcitabine		174	25	5.5

RR: Response rate; MST: Median survival time; NA: Not applicable.